| 1062.24 -14.95 (-1.39%) | 01-14 14:05 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1324.45 | 1-year : | 1546.96 |
| Resists | First : | 1133.94 | Second : | 1324.45 |
| Pivot price | 1075.01 |
|||
| Supports | First : | 1037.02 | Second : | 977.11 |
| MAs | MA(5) : | 1074.33 |
MA(20) : | 1071.3 |
| MA(100) : | 908.61 |
MA(250) : | 838.46 |
|
| MACD | MACD : | 13.8 |
Signal : | 17.7 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 41.3 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 1133.94 | Low : | 623.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LLY ] has closed above bottom band by 31.2%. Bollinger Bands are 56% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1091.6 - 1096.91 | 1096.91 - 1102.14 |
| Low: | 1053.37 - 1060.07 | 1060.07 - 1066.66 |
| Close: | 1064.77 - 1075.4 | 1075.4 - 1085.88 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Wed, 14 Jan 2026
LLY Shows Positive Momentum Amid Obesity Drug Industry Developme - GuruFocus
Wed, 14 Jan 2026
BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY) - TipRanks
Wed, 14 Jan 2026
Eli Lilly and Company $LLY is Wealth Advisory Solutions LLC's 4th Largest Position - MarketBeat
Wed, 14 Jan 2026
Eli Lilly and Company $LLY Stock Holdings Boosted by S Bank Fund Management Ltd - MarketBeat
Tue, 13 Jan 2026
Eli Lilly Expands Bipolar Disorder Pipeline With New Phase 2 Brenipatide Trial - TipRanks
Tue, 13 Jan 2026
Nvidia Drives 70% Drug‑Discovery Cost Crash; Lilly Bets $1B - Eli Lilly and Co (NYSE:LLY), NVIDIA (NASDAQ:NVDA) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 895 (M) |
| Held by Insiders | 8.9313e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 7,250 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.873e+010 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 480.39 |
| Profit Margin | 0 % |
| Operating Margin | 30.9 % |
| Return on Assets (ttm) | 48.2 % |
| Return on Equity (ttm) | 17.6 % |
| Qtrly Rev. Growth | 5.942e+010 % |
| Gross Profit (p.s.) | 145.67 |
| Sales Per Share | 260.72 |
| EBITDA (p.s.) | 1.33351e+011 |
| Qtrly Earnings Growth | 20.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 16,060 (M) |
| PE Ratio | 0 |
| PEG Ratio | 33.1 |
| Price to Book value | 2.21 |
| Price to Sales | 4.08 |
| Price to Cash Flow | 14.83 |
| Dividend | 0 |
| Forward Dividend | 6.55e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|